Bucheli J, Aeschlimann J, Gloor B
Klin Monbl Augenheilkd. 1980;177(2):146-50. doi: 10.1055/s-2008-1057626.
The selective beta-1 blocker Metoprolol was tested for a period of one month in a double-blind trial involving 36 patients with open-angle glaucoma or intraocular hypertension in whom the substance was applied twice daily to the eye in concentrations of 1, 2, 4 and 8%. At all these concentrations the intraocular pressure showed a reduction of 23%. The concentrations over 1% were less well tolerated, the difference being statistically significant; the patients concerned complained of an unpleasant burning sensation for 30 seconds after the application. The subjective intolerance shown increased in proportion to the concentration. It is not clear whether the solvent used contributed to the intolerance. The Metoprolol drops had no effect on pupillary diameter, blood pressure or resting pulse. An important finding was that during the one month's treatment there was no fall-off in the effectiveness of the preparation, i.e., the reduction in intraocular pressure and duration of action showed no diminution such as is seen, for example, with Timolol.
在一项双盲试验中,对36例开角型青光眼或高眼压症患者进行了为期一个月的选择性β-1阻滞剂美托洛尔测试。在该试验中,该药物以1%、2%、4%和8%的浓度每日两次滴眼。在所有这些浓度下,眼压均降低了23%。浓度超过1%时耐受性较差,差异具有统计学意义;相关患者在滴眼后30秒会抱怨有不愉快的烧灼感。所表现出的主观不耐受程度与浓度成正比。尚不清楚所用溶剂是否导致了不耐受。美托洛尔滴眼液对瞳孔直径、血压或静息脉搏无影响。一个重要的发现是,在为期一个月的治疗期间,该制剂的有效性没有下降,即眼压降低程度和作用持续时间没有像噻吗洛尔那样出现减弱。